These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 27443611)

  • 41. Immune surveillance and immunotherapy: lessons from carbohydrate mimotopes.
    Pashov A; Monzavi-Karbassi B; Kieber-Emmons T
    Vaccine; 2009 May; 27(25-26):3405-15. PubMed ID: 19200843
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.
    Keitel WA; Campbell JD; Treanor JJ; Walter EB; Patel SM; He F; Noah DL; Hill H
    J Infect Dis; 2008 Nov; 198(9):1309-16. PubMed ID: 18808338
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.
    Bernstein DI; Edwards KM; Dekker CL; Belshe R; Talbot HK; Graham IL; Noah DL; He F; Hill H
    J Infect Dis; 2008 Mar; 197(5):667-75. PubMed ID: 18260764
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans.
    Zangwill KM; Treanor JJ; Campbell JD; Noah DL; Ryea J
    J Infect Dis; 2008 Feb; 197(4):580-3. PubMed ID: 18237269
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation.
    Hem SL; Hogenesch H
    Expert Rev Vaccines; 2007 Oct; 6(5):685-98. PubMed ID: 17931150
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.
    Treanor JJ; Campbell JD; Zangwill KM; Rowe T; Wolff M
    N Engl J Med; 2006 Mar; 354(13):1343-51. PubMed ID: 16571878
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature.
    Epstein SL
    J Infect Dis; 2006 Jan; 193(1):49-53. PubMed ID: 16323131
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA-A2/K(b) transgenic mice.
    Plotnicky H; Cyblat-Chanal D; Aubry JP; Derouet F; Klinguer-Hamour C; Beck A; Bonnefoy JY; Corvaïa N
    Virology; 2003 May; 309(2):320-9. PubMed ID: 12758178
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.
    Epstein SL; Tumpey TM; Misplon JA; Lo CY; Cooper LA; Subbarao K; Renshaw M; Sambhara S; Katz JM
    Emerg Infect Dis; 2002 Aug; 8(8):796-801. PubMed ID: 12141964
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epitope spreading in immune-mediated diseases: implications for immunotherapy.
    Vanderlugt CL; Miller SD
    Nat Rev Immunol; 2002 Feb; 2(2):85-95. PubMed ID: 11910899
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells.
    Benton KA; Misplon JA; Lo CY; Brutkiewicz RR; Prasad SA; Epstein SL
    J Immunol; 2001 Jun; 166(12):7437-45. PubMed ID: 11390496
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA.
    Ulmer JB; Fu TM; Deck RR; Friedman A; Guan L; DeWitt C; Liu X; Wang S; Liu MA; Donnelly JJ; Caulfield MJ
    J Virol; 1998 Jul; 72(7):5648-53. PubMed ID: 9621023
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity.
    Liang S; Mozdzanowska K; Palladino G; Gerhard W
    J Immunol; 1994 Feb; 152(4):1653-61. PubMed ID: 8120375
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influenza A subtype cross-protection after immunization of outbred mice with a purified chimeric NS1/HA2 influenza virus protein.
    Mbawuike IN; Dillion SB; Demuth SG; Jones CS; Cate TR; Couch RB
    Vaccine; 1994 Nov; 12(14):1340-8. PubMed ID: 7856302
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Generation and in vivo persistence of polarized Th1 and Th2 memory cells.
    Swain SL
    Immunity; 1994 Oct; 1(7):543-52. PubMed ID: 7600283
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cross-subtype protection in humans during sequential, overlapping, and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses.
    Sonoguchi T; Naito H; Hara M; Takeuchi Y; Fukumi H
    J Infect Dis; 1985 Jan; 151(1):81-8. PubMed ID: 3965596
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.
    Hoft DF; Lottenbach K; Goll JB; Hill H; Winokur PL; Patel SM; Brady RC; Chen WH; Edwards K; Creech CB; Frey SE; Blevins TP; Salomon R; Belshe RB
    J Infect Dis; 2016 Oct; 214(7):1020-9. PubMed ID: 27443611
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus.
    Carter NJ; Plosker GL
    BioDrugs; 2008; 22(5):279-92. PubMed ID: 18778110
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines.
    Chada KE; Forshee R; Golding H; Anderson S; Yang H
    Vaccine; 2017 May; 35(24):3162-3170. PubMed ID: 28483200
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human genetics and responses to influenza vaccination: clinical implications.
    Lambkin R; Novelli P; Oxford J; Gelder C
    Am J Pharmacogenomics; 2004; 4(5):293-8. PubMed ID: 15462607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.